Details of the Drug

General Information of Drug (ID: DM4EWNS)

Drug Name
Cinoxacin
Synonyms
Cinobac; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Cinx; Clinoxacin; Uronorm; Azolinic Acid; C 8645; Lilly 64716; TNP00246; Cinobac (TN); Cinoxacine [INN-French]; Cinoxacino [INN-Spanish]; Cinoxacinum [INN-Latin]; Cinoxacin (JAN/USP/INN); Cinoxacin [USAN:BAN:INN:JAN]; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Urinary tract infection GC08 Approved [1]
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 262.22
Logarithm of the Partition Coefficient (xlogp) 2.1
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 7
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [2]
Bioavailability
72.5% of drug becomes completely available to its intended biological destination(s) [3]
Elimination
60% of drug is excreted from urine in the unchanged form [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 1.5 hours [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 63.68603 micromolar/kg/day [5]
Chemical Identifiers
Formula
C12H10N2O5
IUPAC Name
1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
Canonical SMILES
CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3
InChI
InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)
InChIKey
VDUWPHTZYNWKRN-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2762
ChEBI ID
CHEBI:3716
CAS Number
28657-80-9
DrugBank ID
DB00827
TTD ID
D07UXP
ACDINA ID
D00947

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Inhibitor [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
HLA class II histocompatibility antigen, DP alpha 1 chain (HLA-DPA1) OT7OG7Y2 DPA1_HUMAN Gene/Protein Processing [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cinoxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Idarubicin DMM0XGL Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Idarubicin. Acute myeloid leukaemia [2A60] [8]
Aminophylline DML2NIB Moderate Decreased metabolism of Cinoxacin caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [9]
Temozolomide DMKECZD Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Temozolomide. Brain cancer [2A00] [8]
Lomustine DMMWSUL Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [8]
Thiotepa DMIZKOP Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [8]
Ketoprofen DMRKXPT Moderate Additive CNS depression effects by the combination of Cinoxacin and Ketoprofen. Chronic pain [MG30] [10]
Capecitabine DMTS85L Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [8]
Mestranol DMG3F94 Moderate Decreased absorption of Cinoxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [11]
Mycophenolic acid DMRBMAU Moderate Altered absorption of Cinoxacin due to GI flora changes caused by Mycophenolic acid. Crohn disease [DD70] [12]
Procarbazine DMIK367 Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [8]
Didanosine DMI2QPE Moderate Decreased absorption of Cinoxacin due to formation of complexes caused by Didanosine. Human immunodeficiency virus disease [1C60-1C62] [13]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [14]
Meclofenamic acid DM05FXR Moderate Additive CNS stimulant effects by the combination of Cinoxacin and Meclofenamic acid. Inflammatory spondyloarthritis [FA92] [15]
Iron DMAP8MV Moderate Decreased absorption of Cinoxacin due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [16]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Cinoxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [17]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [8]
Fludarabine DMVRLT7 Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [8]
Mercaptopurine DMTM2IK Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Mercaptopurine. Mature B-cell lymphoma [2A85] [8]
Cytarabine DMZD5QR Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Cytarabine. Mature B-cell lymphoma [2A85] [8]
Mechlorethamine DM0CVXA Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Mechlorethamine. Mature T-cell lymphoma [2A90] [8]
Dacarbazine DMNPZL4 Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Dacarbazine. Melanoma [2C30] [8]
Ethinyl estradiol DMODJ40 Moderate Decreased absorption of Cinoxacin due to formation of complexes caused by Ethinyl estradiol. Menopausal disorder [GA30] [11]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Cinoxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [18]
Melphalan DMOLNHF Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Melphalan. Multiple myeloma [2A83] [8]
Deflazacort DMV0RNS Major Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Deflazacort. Muscular dystrophy [8C70] [19]
Hydroxyurea DMOQVU9 Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Hydroxyurea. Myeloproliferative neoplasm [2A20] [8]
Busulfan DMXYJ9C Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Busulfan. Myeloproliferative neoplasm [2A20] [8]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Cinoxacin and Bupropion. Nicotine use disorder [6C4A] [20]
Carboplatin DMG281S Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Carboplatin. Ovarian cancer [2C73] [8]
Topotecan DMP6G8T Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Topotecan. Ovarian cancer [2C73] [8]
Aspirin DM672AH Moderate Additive CNS stimulant effects by the combination of Cinoxacin and Aspirin. Pain [MG30-MG3Z] [15]
Diflunisal DM7EN8I Moderate Additive CNS depression effects by the combination of Cinoxacin and Diflunisal. Pain [MG30-MG3Z] [10]
Ibuprofen DM8VCBE Moderate Additive CNS depression effects by the combination of Cinoxacin and Ibuprofen. Pain [MG30-MG3Z] [10]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Cinoxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [21]
Salsalate DM13P4C Moderate Additive CNS stimulant effects by the combination of Cinoxacin and Salsalate. Rheumatoid arthritis [FA20] [10]
Oxaprozin DM9UB0P Moderate Additive CNS stimulant effects by the combination of Cinoxacin and Oxaprozin. Rheumatoid arthritis [FA20] [10]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Dexamethasone. Rheumatoid arthritis [FA20] [19]
Dactinomycin DM2YGNW Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Dactinomycin. Solid tumour/cancer [2A00-2F9Z] [8]
Methylprednisolone DM4BDON Major Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Methylprednisolone. Solid tumour/cancer [2A00-2F9Z] [19]
Ifosfamide DMCT3I8 Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [8]
Docetaxel DMDI269 Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [8]
Mitoxantrone DMM39BF Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [8]
Prednisolone DMQ8FR2 Major Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Prednisolone. Solid tumour/cancer [2A00-2F9Z] [19]
Taxol DMUOT9V Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [8]
Doxorubicin DMVP5YE Minor Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Doxorubicin. Solid tumour/cancer [2A00-2F9Z] [8]
⏷ Show the Full List of 45 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Erythrosine sodium anhydrous E00324 27872 Colorant
Quinoline yellow WS E00309 24671 Colorant
Sodium lauryl sulfate E00464 3423265 Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF E00255 17730 Colorant
Food blue 1 aluminum lake E00512 11979396 Colorant
Gelatin E00630 Not Available Other agent
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Cyclomethicone E00203 10913 Emollient; Humectant; Viscosity-controlling agent
Pregelatinized starch E00674 Not Available Binding agent; Diluent; Disintegrant
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Cinoxacin 250mg capsule 250mg Capsule Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 BDDCS applied to over 900 drugs
3 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7.
7 Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chem Res Toxicol. 2015 May 18;28(5):927-34. doi: 10.1021/tx5005248. Epub 2015 Apr 3.
8 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
9 Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93. [PMID: 3542945]
10 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
11 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
12 Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
13 Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
14 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
15 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
16 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
17 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
18 Canadian Pharmacists Association.
19 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
20 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
21 Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.